Comparing treatment goals for psoriasis with treatment decisions in daily practice: Results from a prospective cohort of patients with psoriasis treated with biologics: BioCAPTURE

British Journal of Dermatology

Volumn 171, Issue 5, 2014, Pages 1091-1098

  Zweegers, J ^a   Van Den Reek, J M P A ^a   Van De Kerkhof, P C M ^a   Otero, M E ^a   Ossenkoppele, P M ^b   Njoo, M D ^b   Mommers, J M ^c   Koetsier, M I A ^d   Arnold, W P ^e   Sybrandy Fleuren, B A M ^f   Kuijpers, A L A ^g   Andriessen, M P M ^h   Kievit, W ^a   De Jong, E M G J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TWENTEBORG HOSPITAL   (Netherlands)

^c ST ANNA HOSPITAL   (Netherlands)

^d GELRE HOSPITALS   (Netherlands)

^e GELDERSE VALLEI HOSPITAL   (Netherlands)

^f SLINGELAND HOSPITAL   (Netherlands)

^g MÁXIMA MEDICAL CENTER   (Netherlands)

^h JEROEN BOSCH HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIPSORIASIS AGENT; CYCLOSPORIN A; DITHRANOL; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PRESCRIPTION DRUG; USTEKINUMAB; BIOLOGICAL FACTOR; DERMATOLOGICAL AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ADD ON THERAPY; ADULT; AMBULATORY CARE; ARTICLE; BIOLOGICAL THERAPY; CLINICAL PRACTICE; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; DERMATOLOGIST; DERMATOLOGY LIFE QUALITY INDEX; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PHYSICIAN ATTITUDE; PRESCRIPTION; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; QUALITY OF LIFE; REGISTER; SOMNOLENCE; SYSTEMIC THERAPY; TOPICAL TREATMENT; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT; CLINICAL TRIAL; COMPARATIVE STUDY; DECISION MAKING; DRUG COMBINATION; MIDDLE AGED; MOTIVATION; MULTICENTER STUDY; PROSPECTIVE STUDY;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL FACTORS; DECISION MAKING; DERMATOLOGIC AGENTS; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; FEMALE; GOALS; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSORIASIS; QUALITY OF LIFE; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 84911438894     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13137     Document Type: Article

References (21)

1. Nestle FO, Kaplan DH, Barker J,. Psoriasis. N Engl J Med 2009; 361: 496-509.
2. Armstrong AW, Schupp C, Wu J, Bebo B,. Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003-2011. PLOS ONE 2012; 7: e52935.
3. Mrowietz U, Kragballe K, Reich K, et al,. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011; 303: 1-10.
4. Armstrong AW, Robertson AD, Wu J, et al,. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011. JAMA Dermatol 2013; 149: 1180-5.
5. Nast A, Mrowietz U, Kragballe K, et al,. Barriers to the prescription of systemic therapies for moderate-to-severe psoriasis-a multinational cross-sectional study. Arch Dermatol Res 2013; 305: 899-907.
6. Mrowietz U, Kragballe K, Nast A, Reich K,. Strategies for improving the quality of care in psoriasis with the use of treatment goals-a report on an implementation meeting. J Eur Acad Dermatol Venereol 2011; 25 (Suppl. 3): 1-13.
7. Mrowietz U, Kragballe K, Reich K, et al,. An assessment of adalimumab efficacy in three Phase III clinical trials using the European Consensus Programme criteria for psoriasis treatment goals. Br J Dermatol 2013; 168: 374-80.
8. Garcia-Doval I, Carretero G, Vanaclocha F, et al,. Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials. Arch Dermatol 2012; 148: 463-70.
9. Fredriksson T, Pettersson U,. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978; 157: 238-44.
10. Finlay AY, Basra MK, Piguet V, Salek MS,. Dermatology Life Quality Index (DLQI): a paradigm shift to patient-centered outcomes. J Invest Dermatol 2012; 132: 2464-5.
11. Basra MK, Fenech R, Gatt RM, et al,. The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results. Br J Dermatol 2008; 159: 997-1035.
12. Van Lümig PP, Driessen RJ, Boezeman JB, et al,. Long-term efficacy of etanercept for psoriasis in daily practice. Br J Dermatol 2012; 166: 445-7.
13. Kievit W, Fransen J, Oerlemans AJ, et al,. The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice. Ann Rheum Dis 2007; 66: 1473-8.
14. Shear NH, Hartmann M, Toledo-Bahena M,. Long-term efficacy and safety of infliximab maintenance therapy in patients with plaque-type psoriasis in real-world practice. Br J Dermatol 2014; 171: 631-41.
15. Mattei PL, Corey KC, Kimball AB,. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol 2014; 28: 333-7.
16. Grigor C, Capell H, Stirling A, et al,. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004; 364: 263-9.
17. Stark Casagrande S, Fradkin JE, Saydah SH, et al,. The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988-2010. Diabetes Care 2013; 36: 2271-9.
18. McLaughlin VV, Gaine SP, Howard LS, et al,. Treatment goals of pulmonary hypertension. J Am Coll Cardiol 2013; 62 (Suppl. 25): D73-81.
19. Cushman WC, Evans GW, Byington RP, et al,. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1575-85.
20. Cooper-Dehoff RM, Gong Y, Handberg EM, et al,. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 2010; 304: 61-8.
21. van Hulst LT, Kievit W, van Bommel R, et al,. Rheumatoid arthritis patients and rheumatologists approach the decision to escalate care differently: results of a maximum difference scaling experiment. Arthritis Care Res (Hoboken) 2011; 63: 1407-14.